眼科疾病治療市場－全球產業規模、佔有率、趨勢、機會和預測：按處方類型、治療方法、最終用戶、地區和競爭格局分類，2021-2031年

全球眼科疾病治療市場預計將從 2025 年的 238.8 億美元大幅成長至 2031 年的 512.4 億美元，複合年成長率達 13.57%。

該市場涵蓋用於治療多種眼科疾病的藥物，例如青光眼、老齡化黃斑部病變和糖尿病視網膜病變。這些藥物旨在透過調節眼內壓、抑制血管生成或減輕發炎等作用機制來維持視力。市場擴張的主要促進因素是全球人口老化以及糖尿病等慢性文明病盛行率的不斷上升，這些疾病顯著增加了視網膜疾病的發生率。此外，開發中國家診斷基礎設施的改善正在逐步擴大患者獲得基本眼科護理的機會。儘管市場潛力巨大，但新型生物製藥的高成本仍阻礙著市場成長，並常常限制低收入地區的患者取得這些藥物。預計到2025年，全球將有11億人患有視力障礙，凸顯了對價格合理的治療方案的迫切需求。然而，嚴格的報銷政策和醫療保健資金不足是高價眼科藥物廣泛應用面臨的挑戰。

市場促進因素

全球糖尿病視網膜病變和其他文明病的日益流行，是眼科疾病治療市場的主要成長要素。久坐的生活方式會導致代謝異常，進而顯著增加需要藥物治療的視網膜併發症。例如，2020年，全球約有107萬人因糖尿病視網膜病變而失明，需要持續接受抗VEGF治療以防止不可逆的視力喪失。病患數量的成長凸顯了龐大的商業性機遇，Eylea系列藥物2023年的全球淨銷售額達到93.8億美元便印證了這一點。此外，眼科藥物遞送系統和新型眼科生物製藥的進步也進一步推動了市場擴張。創新正朝著緩釋技術和雙特異性抗體發展，與傳統的每月注射相比，這些技術可以延長治療間隔並提高患者的依從性。這一趨勢透過改善臨床結果和支持高階定價策略來推動整體市場收入，正如雙特異性抗體 Vabysmo 在 2023 年 24 億美元的銷售額所證明的那樣。

市場挑戰

新型生物製藥的高成本是全球眼科疾病治療市場商業性擴張的主要障礙。儘管這些高價藥物已證實對濕性老齡化黃斑部病變和糖尿病黃斑部水腫等疾病具有臨床療效，但其定價往往超出醫療保險機構和個人支付方的承受能力。因此，嚴格的報銷政策和有限的資金籌措迫使醫療服務提供者優先考慮成本控制而非臨床療效，從而限制了品牌藥的使用。這種經濟壓力導致醫生選擇價格較低的仿單標示外用藥或推遲必要的治療，直接降低了已通過核准的高價藥物的市場佔有率。產業數據顯示，這些經濟限制因素的影響顯而易見：在2025年接受調查的視網膜專科醫生中，約有93%的人表示，由於自付費用不穩定和資金不足，他們會轉而使用成本更低的治療方法。這些變化不僅降低了專有生物製藥生產商的獲利預期，也凸顯了市場對價格波動的敏感性，表明如果沒有永續的報銷模式，先進眼科治療方法的成長潛力將繼續受到價格承受能力的限制。

市場趨勢

用於治療地圖狀萎縮 (GA) 的補體抑制劑的商業化標誌著市場的一個變革性轉折點，為這種先前進行性老齡化黃斑部病變) 開闢了一個新的治療領域。與針對濕性AMD血管生成的標準抗 VEGF 藥物不同，這些新型治療方法抑制補體級聯反應的過度激活，從而延緩視網膜病變的進展。這些First-in-Class的C3 和 C5 抑制劑的快速臨床應用凸顯了對能夠保護非滲出性疾病患者視力的治療方法的迫切需求。 Aperis Pharmaceuticals 的報告也印證了這一強勁的市場前景：其用於治療 GA 的藥物 Syfovre 預計將於 2025 年第三季在美國實現 1.509 億美元的淨銷售額。同時，基因治療產品線的擴展正在推動針對遺傳性視網膜疾病和慢性血管性視網膜病變的一次性根治性治療方法的研發。製藥公司正擴大採用腺結合病毒（AAV）載體將功能性遺傳物質直接遞送至視網膜細胞的方法，旨在克服每月注射等慢性治療的局限性，並實現持續療效。這項策略重點包括對後期臨床試驗的大量資金投入，以奠定基因療法在治療濕性老齡化黃斑部病變（濕性AMD）和糖尿病性黃斑部水腫等疾病方面的實際應用基礎。例如，4D Molecular Therapeutics公司宣布，已於2025年第二季獲得4.17億美元的融資，用於加速其玻璃體內基因療法4D-150的III期臨床試驗。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：眼科疾病治療藥物的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依處方類型（非處方藥、處方眼科藥物）
  • 治療方法（老齡化黃斑部病變、結膜炎、糖尿病黃斑部水腫、糖尿病視網膜病變、乾眼症、眼癌、青光眼等）
  • 依最終使用者（診斷中心、眼科診所、醫院）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美眼科疾病治療藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲眼科疾病藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區眼科疾病治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲眼科疾病治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲眼科疾病治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球眼科疾病治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• Johnson & Johnson
• AbbVie Inc.
• Bayer AG
• Regeneron Pharmaceuticals, Inc.
• Alcon Inc.
• Bausch Health Companies Inc.
• Santen Pharmaceutical Co., Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Optical Disorders Drugs Market is projected to experience substantial growth, expanding from USD 23.88 Billion in 2025 to USD 51.24 Billion by 2031, at a CAGR of 13.57%. This market encompasses pharmaceutical agents developed to treat various ocular pathologies, including glaucoma, age-related macular degeneration, and diabetic retinopathy, by mechanisms such as intraocular pressure regulation, angiogenesis inhibition, or inflammation reduction to preserve vision. The market's expansion is largely driven by a globally aging population and the increasing prevalence of chronic lifestyle diseases, like diabetes, which significantly raise the incidence of retinal conditions. Furthermore, improved diagnostic infrastructure in developing nations is progressively enhancing patient access to essential ophthalmic care. Despite this potential, the high cost of novel biologic therapies continues to impede market growth, often limiting access in lower-income regions. In 2025, an estimated 1.1 billion people worldwide lived with sight loss, highlighting a critical need for affordable therapeutic solutions, yet stringent reimbursement policies and insufficient healthcare funding challenge the broad adoption of premium ocular drugs.

Market Driver

The escalating global incidence of diabetic retinopathy and other lifestyle-related disorders serves as a primary driver for the optical disorders drugs market. Sedentary lifestyles contribute to metabolic conditions, leading to a significant increase in retinal complications requiring pharmacological intervention. For example, in 2020, approximately 1.07 million people globally were blind due to diabetic retinopathy, necessitating continuous anti-VEGF therapies to prevent irreversible vision loss. This growing patient pool underscores the immense commercial opportunity, as evidenced by the Eylea franchise's global net sales totaling $9.38 billion in 2023. Additionally, advancements in ocular drug delivery systems and novel ophthalmic biologics are further propelling market expansion. Innovation is shifting towards sustained-release technologies and bispecific antibodies, which extend treatment intervals and improve patient compliance compared to traditional monthly injections. This trend, exemplified by the $2.4 billion in sales for the bispecific antibody Vabysmo in 2023, enhances clinical outcomes and supports premium pricing strategies, thereby bolstering overall market revenue.

Market Challenge

The high cost of novel biologic therapies represents a significant obstacle to the commercial expansion of the Global Optical Disorders Drugs Market. Although these premium agents demonstrate clinical efficacy for conditions such as wet age-related macular degeneration and diabetic macular edema, their pricing structures frequently exceed the financial capacity of healthcare systems and individual payers. Consequently, strict reimbursement policies and limited funding availability compel healthcare providers to prioritize cost containment over clinical preference, thereby restricting the adoption of branded therapeutics. This financial pressure often leads physicians to opt for cheaper, off-label alternatives or delay necessary treatments, which directly diminishes the market share of approved, higher-priced drugs. The impact of these economic constraints is evident in industry data, with approximately 93% of surveyed retina specialists in 2025 reporting switches to lower-cost therapeutic alternatives due to unreliable copay assistance and funding shortages. Such shifts not only reduce revenue trajectories for manufacturers of proprietary biologic drugs but also underscore the market's susceptibility to pricing sensitivities, indicating that without sustainable reimbursement models, the growth potential of advanced ocular therapies will remain constrained by affordability barriers.

Market Trends

The commercialization of complement inhibitors for geographic atrophy (GA) marks a transformative shift in the market, establishing a new therapeutic segment for this previously untreatable advanced form of dry age-related macular degeneration. Unlike standard anti-VEGF agents that target angiogenesis in wet AMD, these novel therapeutics regulate the overactivation of the complement cascade to slow the expansion of retinal lesions. The rapid clinical uptake of these first-in-class C3 and C5 inhibitors highlights the urgent demand for treatments capable of preserving visual function in non-exudative conditions. The strong market entry is validated by Apellis Pharmaceuticals reporting U.S. net product revenue of $150.9 million for its GA therapy, Syfovre, in Q3 2025. Simultaneously, the expansion of gene therapy pipelines is advancing the development of one-time curative interventions for inherited retinal disorders and chronic vascular retinopathies. Pharmaceutical companies are increasingly utilizing adeno-associated virus (AAV) vectors to deliver functional genetic material directly to retinal cells, aiming for durable efficacy that overcomes the limitations of chronic monthly injections. This strategic focus involves substantial capital investment into late-stage clinical trials to establish genetic medicines as viable foundations for treating conditions like wet AMD and diabetic macular edema, as demonstrated by 4D Molecular Therapeutics' reported cash position of $417 million to fund accelerated Phase 3 development of its intravitreal genetic medicine, 4D-150, in Q2 2025.

Key Market Players

• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• Johnson & Johnson
• AbbVie Inc.
• Bayer AG
• Regeneron Pharmaceuticals, Inc.
• Alcon Inc.
• Bausch Health Companies Inc.
• Santen Pharmaceutical Co., Ltd.

Report Scope

In this report, the Global Optical Disorders Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Optical Disorders Drugs Market, By Prescription Type

• Over-The-Counter Drugs
• Prescription Ophthalmic Drugs

Optical Disorders Drugs Market, By Therapeutics

• Age-Related Macular Degeneration
• Conjunctivitis
• Diabetic Macular Edema
• Diabetic Retinopathy
• Dry Eye
• Eye Cancer
• Glaucoma
• Others

Optical Disorders Drugs Market, By End User

• Diagnostic Centers
• Eye Clinics
• Hospitals

Optical Disorders Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Optical Disorders Drugs Market.

Available Customizations:

Global Optical Disorders Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Optical Disorders Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Prescription Type (Over-The-Counter Drugs, Prescription Ophthalmic Drugs)
  • 5.2.2. By Therapeutics (Age-Related Macular Degeneration, Conjunctivitis, Diabetic Macular Edema, Diabetic Retinopathy, Dry Eye, Eye Cancer, Glaucoma, Others)
  • 5.2.3. By End User (Diagnostic Centers, Eye Clinics, Hospitals)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Optical Disorders Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Prescription Type
  • 6.2.2. By Therapeutics
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Optical Disorders Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Prescription Type
      • 6.3.1.2.2. By Therapeutics
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Optical Disorders Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Prescription Type
      • 6.3.2.2.2. By Therapeutics
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Optical Disorders Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Prescription Type
      • 6.3.3.2.2. By Therapeutics
      • 6.3.3.2.3. By End User

7. Europe Optical Disorders Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Prescription Type
  • 7.2.2. By Therapeutics
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Optical Disorders Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Prescription Type
      • 7.3.1.2.2. By Therapeutics
      • 7.3.1.2.3. By End User
  • 7.3.2. France Optical Disorders Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Prescription Type
      • 7.3.2.2.2. By Therapeutics
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Optical Disorders Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Prescription Type
      • 7.3.3.2.2. By Therapeutics
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Optical Disorders Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Prescription Type
      • 7.3.4.2.2. By Therapeutics
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Optical Disorders Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Prescription Type
      • 7.3.5.2.2. By Therapeutics
      • 7.3.5.2.3. By End User

8. Asia Pacific Optical Disorders Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Prescription Type
  • 8.2.2. By Therapeutics
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Optical Disorders Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Prescription Type
      • 8.3.1.2.2. By Therapeutics
      • 8.3.1.2.3. By End User
  • 8.3.2. India Optical Disorders Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Prescription Type
      • 8.3.2.2.2. By Therapeutics
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Optical Disorders Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Prescription Type
      • 8.3.3.2.2. By Therapeutics
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Optical Disorders Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Prescription Type
      • 8.3.4.2.2. By Therapeutics
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Optical Disorders Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Prescription Type
      • 8.3.5.2.2. By Therapeutics
      • 8.3.5.2.3. By End User

9. Middle East & Africa Optical Disorders Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Prescription Type
  • 9.2.2. By Therapeutics
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Optical Disorders Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Prescription Type
      • 9.3.1.2.2. By Therapeutics
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Optical Disorders Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Prescription Type
      • 9.3.2.2.2. By Therapeutics
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Optical Disorders Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Prescription Type
      • 9.3.3.2.2. By Therapeutics
      • 9.3.3.2.3. By End User

10. South America Optical Disorders Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Prescription Type
  • 10.2.2. By Therapeutics
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Optical Disorders Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Prescription Type
      • 10.3.1.2.2. By Therapeutics
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Optical Disorders Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Prescription Type
      • 10.3.2.2.2. By Therapeutics
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Optical Disorders Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Prescription Type
      • 10.3.3.2.2. By Therapeutics
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Optical Disorders Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd.
• 15.3. Pfizer Inc.
• 15.4. Johnson & Johnson
• 15.5. AbbVie Inc.
• 15.6. Bayer AG
• 15.7. Regeneron Pharmaceuticals, Inc.
• 15.8. Alcon Inc.
• 15.9. Bausch Health Companies Inc.
• 15.10. Santen Pharmaceutical Co., Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer